Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity.
AuthorsPointon A, Abi-Gerges N, Cross MJ, Sidaway JE,
JournalToxicol Sci
PubMed ID23315586
'Morphological damage to cardiomyocytes or loss of viability (structural cardiotoxicity) is a common cause of attrition in preclinical and clinical drug development. Currently, no predictive in vitro approaches are available to detect this liability early in drug discovery, and knowledge of the mechanisms involved is limited. Human embryonic stem cell-derived ... More